APOLLO_SV;count;-7999775
CHEBI;3'-phospho-5'-adenylyl sulfate;-7999976
CHEBI;4'-hydroxydiclofenac;-7999975
CHEBI;5'-hydroxyomeprazole;-7999974
CHEBI;5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate;-7999973
CHEBI;7-ethoxyresorufin;-7999972
CHEBI;Midazolam;-7999967
CHEBI;NAD;-7999966
CHEBI;NADH;-7999965
CHEBI;NADPH;-7999964
CHEBI;UDP-alpha-D-glucuronic acid;-7999958
CHEBI;alkaline earth coordination entity;-7999955
CHEBI;amiodarone;-7999954
CHEBI;atorvastatin;-7999952
CHEBI;azole;-7999951
CHEBI;benzimidazoles;-7999950
CHEBI;benzofurans;-7999949
CHEBI;benzothiazepine;-7999948
CHEBI;biological role;-7999946
CHEBI;biomacromolecule;-7999944
CHEBI;carbon group molecular entity;-7999942
CHEBI;carbon oxoacid;-7999941
CHEBI;carboxylic acid;-7999940
CHEBI;carboxylic ester;-7999939
CHEBI;chemical entity;-7999781
CHEBI;chemical substance;-7999934
CHEBI;coordination entity;-7999932
CHEBI;cytochrome P450;-7999929
CHEBI;delta-lactone;-7999926
CHEBI;dextromethorphan;-7999923
CHEBI;dextrorphan;-7999922
CHEBI;diazole;-7999921
CHEBI;diclofenac;-7999920
CHEBI;dihydroxy monocarboxylic acid;-7999918
CHEBI;diltiazem;-7999917
CHEBI;ester;-7999910
CHEBI;fluconazole;-7999908
CHEBI;fluvastatin;-7999907
CHEBI;glutathione;-7999904
CHEBI;heme-thiolate protein;-7999901
CHEBI;hemoprotein;-7999900
CHEBI;heteroarene;-7999899
CHEBI;heteroatomic molecular entity;-7999898
CHEBI;heteroorganic entity;-7999897
CHEBI;hydroxy carboxylic acid;-7999896
CHEBI;hydroxy monocarboxylic acid;-7999895
CHEBI;imidazoles;-7999893
CHEBI;information biomacromolecule;-7999888
CHEBI;inhibitor;-7999887
CHEBI;iron protein;-7999886
CHEBI;itraconazole;-7999885
CHEBI;ketoconazole;-7999884
CHEBI;lactone;-7999883
CHEBI;lovastatin;-7999881
CHEBI;macromolecule;-7999879
CHEBI;magnesium coordination entity;-7999878
CHEBI;magnesium dichloride;-7999877
CHEBI;magnesium halide;-7999876
CHEBI;main group molecular entity;-7999875
CHEBI;main-group coordination entity;-7999874
CHEBI;metabolite;-7999870
CHEBI;metalloprotein;-7999869
CHEBI;mixture;-7999868
CHEBI;molecular entity;-7999867
CHEBI;monocyclic heteroarene;-7999865
CHEBI;nucleic acid;-7999860
CHEBI;omeprazole;-7999858
CHEBI;organic cyclic compound;-7999857
CHEBI;organic heterobicyclic compound;-7999856
CHEBI;organic heterocyclic compound;-7999855
CHEBI;organic heteropolycyclic compound;-7999854
CHEBI;organic heterotetracyclic compound;-7999853
CHEBI;organic heterotricyclic compound;-7999852
CHEBI;organic molecular entity;-7999851
CHEBI;organic molecule;-7999850
CHEBI;organochalcogen compound;-7999849
CHEBI;organooxygen compound;-7999848
CHEBI;p-block molecular entity;-7999846
CHEBI;phenoxazine;-7999842
CHEBI;polyatomic entity;-7999841
CHEBI;polynucleotide;-7999840
CHEBI;protein;-7999838
CHEBI;racemate;-7999836
CHEBI;resorufin;-7999830
CHEBI;ribonucleic acid;-7999829
CHEBI;rosuvastatin;-7999828
CHEBI;simvastatin;-7999825
CHEBI;triazolam;-7999819
CHEBI;triazole;-7999818
CHEBI;triazolobenzodiazepine;-7999817
CHMO;absorption of material;-7999957
CL;cultured cell;-7999931
CL;experimentally modified cell in vitro;-7999909
CLO;293-derived cell;-7999813
CLO;CHO cell;-7999971
CLO;Caco-2 cell;-7999970
CLO;cell line;-7999786
CLO;cell line cell;-7999937
Concept Class;PDDI or NPDI Test Class;-9990000
DIDEO;293 transfected cell;-7999814
DIDEO;7-ethoxyresorufin O-deethylation;-7999812
DIDEO;CHO transfected cell;-7999811
DIDEO;E. coli recombinant protein production host cell;-7999810
DIDEO;Fa2N-4 cell;-7999809
DIDEO;HBG BC2 cell;-7999808
DIDEO;Hep G2 cell;-7999807
DIDEO;Hep G2 transfected cell;-7999806
DIDEO;HepaRG cell;-7999805
DIDEO;U.S. Food and Drug Administration drug label;-7999804
DIDEO;absorbability;-7999803
DIDEO;absorbability measurement datum;-7999802
DIDEO;adverse drug reaction causality evaluation protocol;-7999799
DIDEO;area under the curve ratio;-7999796
DIDEO;baculovirus-insect recombinant protein production host cell;-7999794
DIDEO;bioavailability;-7999793
DIDEO;bioavailability measurement datum;-7999792
DIDEO;bioavailability ratio;-7999791
DIDEO;bufuralol 1'-hydroxylation;-7999790
DIDEO;bupropion hydroxylation;-7999789
DIDEO;clearance measurement datum;-7999780
DIDEO;clinically relevant potential drug-drug interaction;-7999778
DIDEO;coumarin 7-hydroxylation;-7999776
DIDEO;cryopreserved human hepatocyte population;-7999774
DIDEO;data item about biological process;-7999773
DIDEO;data item from extrapolation;-7999772
DIDEO;dextromethorphan O-demethylation;-7999771
DIDEO;diclofenac 4'-hydroxylation;-7999770
DIDEO;drug absorbability assay;-7999769
DIDEO;drug bioavailability assay;-7999767
DIDEO;drug co-administration;-7999766
DIDEO;drug first pass metabolism assay;-7999765
DIDEO;drug maximum concentration assay;-7999764
DIDEO;drug maximum concentration measurement datum;-7999763
DIDEO;drug maximum concentration ratio;-7999762
DIDEO;drug package AUC information;-7999760
DIDEO;drug package insert;-7999759
DIDEO;drug-drug interaction;-7999757
DIDEO;drug-drug interaction description;-7999756
DIDEO;drug-drug interaction description from FDA label information;-7999755
DIDEO;drug-drug interaction description from drug package insert;-7999754
DIDEO;drug-drug interaction effect;-7999753
DIDEO;drug-drug interaction evidence;-7999752
DIDEO;drug-drug interaction management option;-7999751
DIDEO;efflux ratio;-7999750
DIDEO;evidence data item;-7999747
DIDEO;evidence information content entity;-7999746
DIDEO;evidence information from CYP450 drug metabolism identification experiment;-7999745
DIDEO;evidence information from CYP450 human microsome drug metabolism identification experiment;-7999744
DIDEO;evidence information from CYP450 human microsome drug metabolism identification experiment using antibody inhibitors;-7999743
DIDEO;evidence information from CYP450 human microsome drug metabolism identification experiment using chemical inhibitors;-7999742
DIDEO;evidence information from CYP450 human microsome drug metabolism inhibition experiment;-7999741
DIDEO;evidence information from CYP450 metabolic enzyme inhibition experiment;-7999740
DIDEO;evidence information from CYP450 recombinant drug metabolism identification experiment;-7999739
DIDEO;evidence information from CYP450 recombinant drug metabolism identification experiment using antibody inhibitors;-7999738
DIDEO;evidence information from CYP450 recombinant drug metabolism identification experiment using chemical inhibitors;-7999737
DIDEO;evidence information from CYP450 recombinant drug metabolism inhibition experiment;-7999736
DIDEO;evidence information from OATP1B1 inhibition experiment;-7999735
DIDEO;evidence information from OATP1B1 inhibition experiment using overexpressed cell lines;-7999734
DIDEO;evidence information from OATP1B1 transport protein identification experiment;-7999733
DIDEO;evidence information from OATP1B1 transport protein identification experiment using overexpressed cell lines;-7999732
DIDEO;evidence information from OATP1B3 inhibition experiment;-7999731
DIDEO;evidence information from OATP1B3 inhibition experiment using overexpressed cell lines;-7999730
DIDEO;evidence information from OATP1B3 transport protein identification experiment;-7999729
DIDEO;evidence information from OATP1B3 transport protein identification experiment using overexpressed cell lines;-7999728
DIDEO;evidence information from a publicly reported observation-based adverse drug event report;-7999727
DIDEO;evidence information from an evaluated observation-based case-report of a drug interaction;-7999726
DIDEO;evidence information from an observation-based case-report of a drug interaction;-7999725
DIDEO;evidence information from clinical study;-7999724
DIDEO;evidence information from drug metabolism identification experiment;-7999723
DIDEO;evidence information from drug metabolism inhibition experiment;-7999722
DIDEO;evidence information from drug-drug interaction clinical trial;-7999721
DIDEO;evidence information from genotyped pharmacokinetic trial;-7999720
DIDEO;evidence information from non-randomized drug-drug interaction clinical trial;-7999719
DIDEO;evidence information from observation-based adverse drug event report;-7999718
DIDEO;evidence information from observation-based report;-7999717
DIDEO;evidence information from observational drug-drug interaction study;-7999716
DIDEO;evidence information from observational pharmacokinetic study;-7999715
DIDEO;evidence information from observational study;-7999714
DIDEO;evidence information from p-glycoprotein inhibition experiment;-7999713
DIDEO;evidence information from p-glycoprotein inhibition experiment using Caco 2 cell lines;-7999712
DIDEO;evidence information from p-glycoprotein inhibition experiment using overexpressed cell lines;-7999711
DIDEO;evidence information from p-glycoprotein transport protein identification experiment;-7999710
DIDEO;evidence information from p-glycoprotein transport protein identification experiment using Caco 2 cell lines;-7999709
DIDEO;evidence information from p-glycoprotein transport protein identification experiment using overexpressed cell lines;-7999708
DIDEO;evidence information from parallel groups drug-drug interaction clinical trial';-7999707
DIDEO;evidence information from pharmacokinetic trial;-7999706
DIDEO;evidence information from phenotyped pharmacokinetic trial;-7999705
DIDEO;evidence information from randomized drug-drug interaction clinical trial;-7999704
DIDEO;evidence information from transport protein identification experiment;-7999703
DIDEO;evidence information from transport protein inhibition experiment;-7999702
DIDEO;evidence material information;-7999701
DIDEO;first pass effect disposition;-7999699
DIDEO;first pass metabolism measurement datum;-7999698
DIDEO;fold;-7999697
DIDEO;freshly isolated human hepatocyte population;-7999696
DIDEO;gastrointestinal functioning;-7999695
DIDEO;half-life ratio;-7999690
DIDEO;hepatic clearance ratio;-7999689
DIDEO;human intestinal epithelial cell population;-7999688
DIDEO;human intestine S9 fraction;-7999687
DIDEO;human intestine cytosolic fraction;-7999686
DIDEO;human liver S9 fraction;-7999685
DIDEO;human liver cytosolic fraction;-7999684
DIDEO;individual human intestinal microsomal fraction;-7999682
DIDEO;individual human liver microsomal fraction;-7999681
DIDEO;information about decrease of pharmacokinetic area under the curve;-7999680
DIDEO;information about increase of pharmacokinetic area under the curve;-7999679
DIDEO;inhibitory constant;-7999678
DIDEO;material entity participant in drug-drug interaction;-7999676
DIDEO;mechanism of interaction information;-7999674
DIDEO;metabolic potential drug-drug interaction;-7999673
DIDEO;metabolism induction potential drug-drug interaction;-7999672
DIDEO;metabolism inhibition potential drug-drug interaction;-7999671
DIDEO;midazolam 1'-hydroxylation;-7999669
DIDEO;narrow therapeutic index;-7999666
DIDEO;net flux ratio;-7999665
DIDEO;nifedipine dehydrogenation;-7999664
DIDEO;number of doses in a day;-7999663
DIDEO;number of liver donors;-7999662
DIDEO;object drug information;-7999661
DIDEO;object drug role;-7999660
DIDEO;observational data item about drug-drug interaction;-7999658
DIDEO;obsolete_evidence information content entity;-7999657
DIDEO;omeprazole 5-hydroxylation;-7999656
DIDEO;paclitaxel 6-alpha hydroxylation;-7999654
DIDEO;percent inhibition;-7999652
DIDEO;pharmacokinetic area under curve;-7999651
DIDEO;pharmacokinetic area under curve information;-7999650
DIDEO;pharmacokinetic interaction signal;-7999649
DIDEO;pharmacokinetic parameter ratio;-7999648
DIDEO;pharmacokinetic parameter ratio decrease;-7999647
DIDEO;pharmacokinetic parameter ratio directionality;-7999646
DIDEO;pharmacokinetic parameter ratio increase;-7999645
DIDEO;pharmacokinetic process;-7999644
DIDEO;phenacetin O-deethylation;-7999643
DIDEO;physiological observation from clinical study data item;-7999642
DIDEO;pooled human intestinal microsomal fraction;-7999641
DIDEO;pooled human liver microsomal fraction;-7999640
DIDEO;potential drug-drug interaction;-7999639
DIDEO;precipitant drug information;-7999638
DIDEO;precipitant drug role;-7999637
DIDEO;primary metabolic clearance enzyme role;-7999636
DIDEO;primary total clearance enzyme role;-7999635
DIDEO;probe subtrate role;-7999634
DIDEO;public adverse event reporting database;-7999631
DIDEO;recombinant protein production host role;-7999630
DIDEO;renal clearance ratio;-7999629
DIDEO;reported drug-drug interaction;-7999628
DIDEO;sandwich cultured hepatocyte population;-7999626
DIDEO;siRNA knockout Caco-2 cell;-7999624
DIDEO;testosterone 6-beta-hydroxylation;-7999619
DIDEO;time to maximum drug concentration ratio;-7999618
DIDEO;transgenic animal hepatocyte population;-7999615
DIDEO;volume of distribution ratio;-7999614
DRON;active ingredient;-7999801
DRON;drug administration;-7999768
DRON;drug product;-7999758
DRON;role of scattered molecular aggregate;-7999627
Domain;Potential drug interactions of natural product drug interactions;-9900000
EFO;genotyping;-7999905
ERO;RNA interference oligonucleotide;-7999961
ERO;RNA oligonucleotide;-7999960
ERO;RNA reagent;-7999959
ERO;nucleic acid reagent;-7999859
ERO;phenotype characterization;-7999843
ERO;siRNA oligonucleotide;-7999826
FMA;Portion of body substance;-7999963
FMA;Portion of plasma;-7999962
GO#GO;catalytic activity;-7999788
GO#GO;cellular process;-7999784
GO#GO;drug metabolic process;-7999761
GO#GO;molecular_function;-7999668
GO;biological regulation;-7999947
GO;biological_process;-7999945
GO;catalytic activity;-7999938
GO;cellular metabolic process;-7999936
GO;cellular_component;-7999935
GO;establishment of localization;-7999911
GO;immunoglobulin complex;-7999892
GO;immunoglobulin complex, circulating;-7999891
GO;import across plasma membrane;-7999890
GO;import into cell;-7999889
GO;localization;-7999882
GO;macromolecular complex;-7999880
GO;metabolic process;-7999871
GO;molecular_function;-7999866
GO;negative regulation of biological process;-7999864
GO;negative regulation of metabolic process;-7999863
GO;negative regulation of transport;-7999862
GO;negative regulation of transporter activity;-7999861
GO;positive regulation of biological process;-7999839
GO;protein complex;-7999837
GO;regulation of biological process;-7999834
GO;regulation of localization;-7999833
GO;regulation of transport;-7999832
GO;regulation of transporter activity;-7999831
GO;transport;-7999821
IDO;enzyme substrate role;-7999912
INO;gene expression;-7999906
INO;overexpression;-7999847
MESH;1-(3-chlorophenyl)piperazine;-7999977
MESH;2-hydroxydesipramine;-7999613
MESH;4-hydroxypropranolol;-7999612
MESH;Abiraterone Acetate;-7999611
MESH;Adrenergic beta-Antagonists;-7999610
MESH;Amphetamine;-7999609
MESH;Anti-Arrhythmia Agents;-7999608
MESH;Antidepressive Agents;-7999607
MESH;Antipsychotic Agents;-7999606
MESH;Antiviral Agents;-7999605
MESH;Barbiturates;-7999603
MESH;Benzodiazepines;-7999602
MESH;CYP2C19 protein, human;-7999596
MESH;CYP3A4 protein, human;-7999595
MESH;Calcium Channel Blockers;-7999601
MESH;Contraceptives, Oral;-7999598
MESH;Cyclosporine;-7999597
MESH;Cytochrome P-450 CYP2D6;-7999594
MESH;Dextrorphan;-7999592
MESH;Ethinyl Estradiol;-7999591
MESH;MCPP protocol;-7999585
MESH;Nordazepam;-7999583
MESH;Paliperidone Palmitate;-7999580
MESH;Phenothiazines;-7999579
MESH;Rifampin;-7999577
MESH;Risperidone;-7999576
MESH;Rivaroxaban;-7999575
MESH;SLCO1B1 protein, human;-7999573
MESH;Valproic Acid;-7999570
MESH;Warfarin;-7999569
MESH;avasimibe;-7999604
MESH;capsid protein p88, Hv190SV;-7999600
MESH;clozapine N-oxide;-7999599
MESH;desmethylsertraline;-7999593
MESH;fimasartan;-7999590
MESH;hydrobupropion;-7999589
MESH;hydroxybupropion;-7999588
MESH;hydroxynefazodone;-7999587
MESH;lopinavir-ritonavir drug combination;-7999586
MESH;norclozapine;-7999584
MESH;norfluoxetine;-7999582
MESH;norverapamil;-7999581
MESH;retinoblastoma protein p95;-7999578
MESH;simvastatin acid;-7999574
MESH;sulforidazine;-7999572
MESH;triazole-dione;-7999571
MOP;deethylation;-7999928
MOP;dehydrogenation;-7999927
MOP;demethylation;-7999925
MOP;hydroxylation;-7999894
NCBITaxon;Escherichia coli;-7999969
NCBITaxon;Homo sapiens;-7999968
OAE;adverse drug event;-7999800
OAE;adverse event;-7999798
OAE;causal adverse drug event;-7999787
OAE;contraindication;-7999777
OAE;severe adverse event;-7999827
OBI;assay;-7999795
OBI;cell pellet;-7999785
OBI;centrifugation;-7999783
OBI;centrifuge pellet role;-7999782
OBI;clinical study design;-7999779
OBI;container;-7999933
OBI;cultured cell population;-7999930
OBI;device;-7999924
OBI;dose specification;-7999914
OBI;enzyme;-7999749
OBI;evaluant role;-7999748
OBI;ex vivo design;-7999700
OBI;gene knock out;-7999694
OBI;genetic transformation;-7999693
OBI;group assignment;-7999692
OBI;group randomization;-7999691
OBI;half maximal effective concentration (EC50);-7999903
OBI;half maximal inhibitory concentration (IC50);-7999902
OBI;in vitro design;-7999683
OBI;manufacturer role;-7999873
OBI;material component separation;-7999677
OBI;material processing;-7999675
OBI;microtiter plate;-7999670
OBI;observation design;-7999659
OBI;organism;-7999655
OBI;parallel group design;-7999653
OBI;processed material;-7999633
OBI;protocol;-7999632
OBI;scattered molecular aggregate;-7999625
OBI;specimen;-7999623
OBI;specimen collection process;-7999822
OBI;study design;-7999622
OBI;supernatant role;-7999621
OBI;target of material addition role;-7999620
OBI;tissue specimen;-7999617
OBI;transfection;-7999616
OBI;value specification;-7999815
OGMS;bodily process;-7999943
OGMS;pathological bodily process;-7999845
OGMS;treatment;-7999820
PDRO.owl#PDRO;active ingredient quantification specification;-7999956
PDRO.owl#PDRO;dose quantification specification;-7999915
PDRO.owl#PDRO;drug product quantification specification;-7999913
PR;multidrug resistance protein 1;-7999667
PR;solute carrier organic anion transporter family member 1B1;-7999824
PR;solute carrier organic anion transporter family member 1B3;-7999823
STATO;area under curve;-7999797
UBERON;anatomical system;-7999953
UBERON;digestive system;-7999919
UBERON;material anatomical entity;-7999872
UO;dimensionless unit;-7999916
UO;percent;-7999844
UO;ratio;-7999835
UO;unit;-7999816
Vocabulary;APOLLO_SV;-7999991
Vocabulary;CHEBI;-7999982
Vocabulary;CHMO;-7999995
Vocabulary;CL;-7999988
Vocabulary;CLO;-7999989
Vocabulary;DRON;-7999992
Vocabulary;EFO;-7999985
Vocabulary;ERO;-7999997
Vocabulary;FMA;-7999983
Vocabulary;GO;-7999993
Vocabulary;GO#GO;-7999987
Vocabulary;IDO;-7999998
Vocabulary;INO;-7999979
Vocabulary;MOP;-7999981
Vocabulary;NCBITaxon;-7999999
Vocabulary;OAE;-8000000
Vocabulary;OBI;-7999994
Vocabulary;OGMS;-7999986
Vocabulary;PDRO.owl#PDRO;-7999978
Vocabulary;PR;-7999996
Vocabulary;STATO;-7999984
Vocabulary;The Potential Drug-drug Interaction and Potential Drug-drug Interaction Evidence Ontology;-9999000
Vocabulary;UBERON;-7999990
Vocabulary;UO;-7999980
